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A Novel Complotype Combination 
Associates with Age-Related Macular 
Degeneration and High Complement 
Activation Levels in vivo
Constantin C. Paun1,2, Yara T. E. Lechanteur1, Joannes M. M. Groenewoud3, Lebriz Altay4, 
Tina Schick4, Mohamed R. Daha5, Sascha Fauser4, Carel B. Hoyng1,  
Anneke I. den Hollander1,2,6 & Eiko K. de Jong1,2
The complement system is the first line of defense against foreign intruders, and deregulation of this 
system has been described in multiple diseases. In age-related macular degeneration (AMD), patients 
have higher complement activation levels compared to controls. Recently, a combination of three single 
nucleotide polymorphisms (SNPs) in genes of the complement system, referred to as a complotype, 
has been described to increase complement activation in vitro. Here we describe a novel complotype 
composed of CFB (rs4151667)-CFB (rs641153)-CFH (rs800292), which is strongly associated with 
both AMD disease status (p = 5.84*10−13) and complement activation levels in vivo (p = 8.31*10−9). 
The most frequent genotype combination of this complotype was associated with the highest 
complement activation levels in both patients and controls. These f indings are relevant in the context 
of complement-lowering treatments for AMD that are currently under development. Patients with a 
genetic predisposition to higher complement activation levels will potentially benefit the most of such 
treatments.
The complement system is part of our innate immunity where it acts as a first line of defense against foreign 
intruders1 and as a surveillance system to discriminate between healthy host tissue, cellular debris and apoptotic 
cells2. The complement system can be triggered through one of its three pathways: the classical pathway (CP), the 
lectin pathway (LP) and the alternative pathway (AP). All three pathways converge at the level of complement 
component 3 (C3), which is cleaved into C3a (a potent proinflammatory molecule) and C3b (an opsonin)1.
After C3 cleavage, a subsequent cascade of enzymatic reactions lead to the formation of the 
membrane-attack-complex, which is responsible for disrupting the target cell membrane by forming transmem-
brane pores3. Unlike the CP and the LP, which need certain triggers to become activated, the AP is always at a low 
level of activation via a process called “tick-over”4, a spontaneous conversion of C3 to a bioactive form C3(H2O)5. 
This conversion leads to a conformational change that allows for the binding of complement factor B (FB), similar to 
C3b5 and, through a series of subsequent steps, forms the initial C3 convertase C3(H2O)Bb1. This convertase cleaves 
C3 molecules into C3a and C3b5,6. In plasma, AP amplification is controlled by complement factor H (FH), which 
inactivates the C3 convertase and catalyses complement factor I (FI) degradation of C3b7. Dysregulation of the 
AP is associated with a number of diseases8, a strong example being age-related macular degeneration (AMD)9–12.
AMD is a progressive retinal disease that leads to vision loss in the elderly population13. It is a multifactorial 
disease caused by both genetic and environmental factors. Several lines of evidence support the involvement 
of the complement system in the pathology of AMD. Some of the highest genetic risk for AMD is conferred by 
single nucleotide polymorphisms (SNPs) in or near genes of the complement system14. Additionally, complement 
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activation levels in plasma/serum are significantly higher in patients compared to controls9–12, and complement 
components have been described in the composition of retinal deposits called drusen, which are a hallmark of 
the disease15.
Currently, AMD therapies that aim to inhibit or lower complement activation are being developed16,17, but it 
has been suggested that one of these inhibitors, lampalizumab, is effective only in a subset of patients that carry 
a specific genotype18. Therefore, it is important to understand the genetic risk factors that influence complement 
activation in order to identify those individuals that would benefit the most from such treatments.
Several studies have evaluated the effect of SNPs on complement activity, and only moderate effects have been 
observed19–21. In vitro studies show that complement activity can increase six-fold when multiple SNPs in the 
complement system interact together20. Such combinations of SNPs in the complement system are called complo-
types. Harris et al. defined the complotype as any inherited pattern of genetic variants in complement genes which 
alters risk for both inflammatory disorders and infectious diseases involving the complement system22. Until 
now, the best studied complotype in vitro is composed of three functional variants from the AP: C3 (rs2230199 
p.R102G), CFB (rs641153 p.R32Q) and CFH (rs800292 p.V62I). All three SNPs are individually associated with 
AMD23–25. Although the presence of all three SNPs led to markedly higher complement activity in vitro, the effect 
of the complotype has so far neither been investigated in human plasma samples, representative of the in vivo 
situation, nor been associated with any disease.
In a recent study, we have found another functional SNP in CFB (rs4151667) to be more strongly associated 
with complement activation9 than the individual SNPs in the most studied complotype (C3 (rs2230199), CFB 
(rs641153) and CFH (rs800292)). The aims of this study, therefore, are: 1) to expand the complotype with the CFB 
variant (rs4151667) we found to be highly associated with complement activity; 2) to evaluate the relation of the 
complotype with complement activation in human plasma samples, representative of the in vivo situation; and 3) 
to investigate the association between the complotype and AMD.
Results
The study was performed in three consecutive steps. First, the individual associations of CFH (rs800292), CFB 
(rs4151667), CFB (rs641153) and C3 (rs2230199) with AMD and with complement activation were verified. Next, 
we determined the most informative complotype for complement activation. Finally, we analyzed the association 
of the resulting complotype with the disease and with complement activation.
Individual association of CFH (rs800292), CFB (rs4151667), CFB (rs641153) and C3 (rs2230199) 
with AMD and complement activation. In a previous study, CFH rs800292, CFB rs4151667, CFB 
rs641153 and C3 rs2230199 were tested for their association with AMD in 2,655 individuals9. For the purpose 
of this study, 387 additional individuals were genotyped, amounting to a total of 3,042 subjects (1,615 AMD and 
1,427 Controls). The mean age was 75 for AMD and 70 for controls. The gender distribution was: 41% males 
to 59% females. All four SNPs were significantly associated with AMD (Supplementary Table 1). SNPs CFH 
rs800292 (minor allele A), CFB rs4151667 (minor allele A) and CFB rs641153 (minor allele A) are protective, 
whereas the C3 rs2230199 (minor allele C) infers increased risk of AMD.
To determine the association of these SNPs with complement activation levels, CFH (rs800292), CFB 
(rs4151667), CFB (rs641153) and C3 (rs2230199) were included in a single general linear model, corrected for 
age, gender, body mass index (BMI) and disease status. The model revealed significant independent associations 
with complement activation levels for all four SNPs. Figure 1 illustrates P-values, mean log-transformed comple-
ment activation levels and genotype distribution for the four tested SNPs.
When we looked at the difference in mean complement activation level between the genotypes for each SNP, 
the high-risk C3 (rs2230199) genotype (GG) showed higher complement activation levels than the heterozy-
gous (CG) and ancestral (CC) genotype. The protective CFH (rs800292) genotype (AA) showed lower comple-
ment activation levels than the other genotypes (Fig. 1). However, a statistically significant difference in mean 
complement levels was only observed between the heterozygous genotype (GA) and the major genotype (GG) 
(p = 0.002), presumably due to the limited number of individuals carrying the AA genotype. The protective CFB 
(rs641153) genotype (AA) and the heterozygous (GA) genotype displayed lower mean complement activation 
levels than the ancestral (GG) genotype. For CFB (rs4151667), the homozygous protective genotype for AMD 
(AA) could not be statistically compared to the homozygous ancestral genotype (TT), due to low number of indi-
viduals in this genotype group. The observed effects are driven by the difference in mean complement activation 
levels between the heterozygous (TA) genotype and the ancestral (TT) genotype (Fig. 1).
The most informative SNP combination in determining complement activation or AMD status. 
As all four SNPs were individually and independently associated with both complement activation and AMD 
status, the next step aimed to assess which combination of SNPs best predicted these associations. It was impossi-
ble to introduce genotype combinations of all 4 SNPs into the model because of the very low samples number of 
individuals in each of the resulting groups. For this reason, only combinations of 3 SNPs were considered.
In order to determine which combination of SNPs could best explain complement activation and disease 
status, two random forest analyses were performed. In the first analysis, the ratio of C3d/C3 as a measure of 
complement activation was used as the dependent variable, whereas the second analysis was classified on AMD 
disease status. Variable importance analyses in both tests revealed that the SNP combination composed of CFB 
(rs4151667)-CFB (rs641153)-CFH (rs800292) was the strongest predictor for both complement activation and 
AMD status (Table 1). For the purpose of clarity, this combination of SNPs will be referred to as the novel com-
plotype in the remainder of the manuscript.
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Association of the novel complotype with AMD. Mathematically, there are 27 possible genotype com-
binations for a complotype composed of three SNPs. To ensure a meaningful interpretation of the statistical 
analyses, we included only those genotype combinations that were represented by at least ten individuals in both 
the patients and controls group. In our cohort, we observed seven genotype combinations that met these criteria. 
The distribution of all genotype combinations in our cohort is shown in Supplementary Table 2.
To determine the association of the novel complotype with AMD, a logistic regression analysis was performed. 
A strong overall association of the novel complotype with AMD (p = 5.84*10−13) was observed. In our analysis 
of the genotype combinations within the novel complotype, the most frequent genotype combination found in 
controls (TT-GG-GG) was set as reference. The logistic regression analyses corrected for age and gender revealed 
that, in comparison to TT-GG-GG, the other six genotype combinations were protective for AMD (Table 2).
Association of the novel complotype with complement activation. Finally, to determine the associ-
ation of the novel complotype with complement activation, a general linear model was built, corrected for age, gen-
der, BMI and disease status. This model showed that the novel complotype was highly associated with complement 
activation levels (p = 8.31*10−9). When we compared the different genotype combinations with one another, the 
TT-GG-GG combination was associated with the highest mean complement activation levels (Fig. 2). The difference 
in mean complement activation levels between all genotype combinations, tested in a post-hoc Bonferroni corrected 
manner, are presented in Supplementary Table 3. When comparing complement activation levels between AMD 
patients and controls, we only observed a significant difference for genotype combination TT-GG-GA (Fig. 2).
Figure 1. Plasma complement activation levels (log-transformed C3d/C3 ratio) for C3, CFH and CFB 
genotype groups. Each genotype per SNP is plotted on the X axis in an individual dot plot. The homozygous 
genotypes conferring increased risk for AMD are indicated in red; the homozygous genotypes that are 
protective for AMD are indicated in green. The number of individuals carrying a specific genotype is 
indicated below each genotype. The Y axis represents the Log-transformed C3d/C3 ratio level as a measure of 
complement activation. The p-values represent the overall significance for each SNP included in the model.
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Discussion
In a large case-control study, we show that carrying multiple AMD protective genotypes for CFB (rs4151667), 
CFB (rs641153) and CFH (rs800292) leads to lower levels of complement activation in plasma compared to the 
most frequent genotype combination of these SNPs in control individuals. This novel complotype was identified 
as the most predictive SNP combination for determining both complement activation levels and AMD status. 
This combination of SNPs, drawn from an in vivo setting, is different from what has previously been suggested on 
the basis of in vitro data20.
It is well established that SNPs in complement components C3, CFB and CFH influence the risk for AMD24–26. 
In this study, we confirmed that four common functional SNPs, CFH (rs800292), CFB (rs4151667), CFB 
(rs641153) and C3 (rs2230199) are associated with AMD. The minor alleles of the CFH and the CFB SNPs are 
protective23,24, whereas the minor allele of the C3 SNP confers increased risk of AMD25. The well-known AMD 
SNP CFH (rs1061170; Tyr402His) was not included in this study because it was not associated with complement 
activation in our previous study9. This SNP was not described to alter AP convertase regulation, but rather it dis-
plays differential binding to C-reactive protein27 and malondialdehyde28.
Higher levels of systemic complement activation in patients compared to controls have been described in multi-
ple studies9,10,12,29. As the proteins encoded by CFH, CFB and C3 are key components of the AP of the complement 
system30, the contribution of these SNPs to disease susceptibility possibly comes from their impact on AP activation.
FH is a major regulator of the AP31. One of the ways in which it down-regulates complement activity is to bind 
C3b as a cofactor for its inactivation32. The A allele (p.62I) of the CFH (rs800292, pV62I) SNP is a gain of function 
variant. In vitro experiments showed that the resulting protein binds more efficiently to C3b than the protein 
resulting from the G allele (p.V62) of this SNP19, thus leading to more complement inhibition. This is in line with 
our results, demonstrating that the CFH (rs800292) GG genotype was associated with decreased risk for AMD 
and lower levels of complement activation than the AA genotype.
FB binds hydrolyzed C3(H2O) or C3b, which is then cleaved by complement factor D to form the AP C3 con-
vertase that cleaves C3 to C3a and C3b22, thus fueling the AP amplification loop. The A (p.32Q) allele of rs641153 
(p.R32Q) leads to a FB protein with decreased potential to form the C3 convertase and amplify complement acti-
vation33. The second CFB SNP (rs4151667) (p.L9H) resides in the signal peptide, and it has been proposed that it 
could alter CFB secretion24. In this study, the A alleles of both CFB SNPs were found to be protective for AMD and 
to lead to lower complement activation levels, even in heterozygous state, than the major homozygous genotype. 








C3 (rs2230199) 5.33 0.06 6.59 1.85
CFB (rs4151667) 13.24 0.20 2.51 0.92
CFB (rs641153) 5.77 0.11 6.08 2.41
CFH (rs800292) 6.07 0.15 13.24 6.57
C3 (rs2230199)-CFB (rs4151667)-CFB (rs641153) 8.83 0.34 8.71 5.07
C3 (rs2230199)-CFB (rs4151667)-CFH (rs800292) 9.08 0.35 13.12 9.66
C3 (rs2230199)-CFB (rs641153)-CFH (rs800292) 10.88 0.33 13.84 11.85
CFB (rs4151667)-CFB (rs641153)-CFH (rs800292) 18.58 0.62 18.47 17.28
C3 (rs2230199)-CFB (rs4151667)-CFB (rs641153)-CFH (rs800292) 10.25 0.49 14.07 15.36
Table 1.  Variable importance scores of C3, CFB and CFH genotypes and genotype combinations on 
complement activation levels and AMD status. Mean decrease accuracy and mean decrease Gini measure 
variable importance in predicting disease status. %IncMSE and IncNode Purity are measures for variable 
importance in predicting complement activation. For all variables, the highest values represent the best 
predictors.





Contols AMD Lower Upper
TT-GG-GG 607 916 5.84*10−13 – – –
TA-GG-GA 47 23 1.01*10−5 0.3 0.174 0.51
TA-GG-GG 55 65 0.131 0.74 0.494 1.096
TT-GA-GA 74 47 6.65*10−7 0.36 0.237 0.535
TT-GA-GG 112 106 3.2*10−4 0.57 0.422 0.775
TT-GG-AA 59 48 0.007 0.56 0.373 0.856
TT-GG-GA 406 370 7.32*10−9 0.58 0.48 0.696
Table 2.  Association between the novel complotype and AMD. The model was established by logistic 
regression analysis, corrected for age and gender. Bonferroni corrected threshold for statistical significance is 
p < 0.008.
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C3 plays a central role in the complement system34. The G (p.102G) allele of C3 (rs2230199, p.R102G) 
decreases the efficiency of regulation of C3b by FH, thus leading to an increase in complement activation. These 
observations are in accordance with the results in the present study, where the GG genotype is associated with 
risk for AMD and displays higher levels of complement activation than the CC genotype (Fig. 1A). Even though it 
plays such an important role, it was not part of the most predictive complotype in the present study.
Several in vitro studies have shown that having multiple SNPs in complement genes would lead to higher 
complement activation20,35. In the present study, the novel complotype composed of CFB(rs4151667)-CFB(rs6
41153)-CFH(rs800292) had a larger effect on complement activation than the initially studied complotype C3 
(rs2230199)-CFB (rs641153)-CFH (rs800292)20 (Table 1). The higher predictive value of the newly described 
complotype with respect to AMD might be related to the fact that it is composed of protective SNPs only rather 
than of a combination of polymorphisms with opposing effects on AMD susceptibility. When comparing the 
strongest effect (OR = 0.3) of this new complotype on the risk of AMD with the odds ratios of the 38 individual 
loci described in the newest AMD GWAS36, we notice that the effect size is close to both the CFH (OR = 0.38) and 
the ARMS2 (OR = 2.81), albeit reverse, locus. It is worth mentioning that the OR of 0.3 for the complotype it is 
seen when comparing TA-GG-GA to TT-GG-GG which has only two alleles difference out of the six.
This study is the first to analyze this specific complotype combination for its association with AMD and com-
plement activity. Although it would have been interesting to study the simultaneous presence of all four geno-
typed SNPs, cohorts even larger than ours are needed to avoid the problem of small genotype combination groups 
that cannot be reliably compared.
Intriguingly, the homozygous genotypes associated with the highest complement activation levels in all three 
SNPs (TT-GG-GG) in the novel complotype are found most frequently in both AMD patients and controls. This 
is in contrast to what was proposed in the theoretical model from22, where the extreme genotype combinations 
were expected to be at the lower end of the carrier frequency spectrum. With fewer than ten individuals for 
patients or controls, the combination of all heterozygous genotypes was rare. The combination where all SNPs had 
the homozygous protective genotypes (AA-AA-AA) was not present in our cohort at all. In our study, therefore, 
the frequency distribution is skewed towards complement-raising genotypes.
This could potentially be explained by the fact that our cohort has a mean age of 73 years and might be 
enriched, therefore, for alleles that promote survival. In this case, the alleles that give higher complement activa-
tion could offer better lifetime protection against infection. However, these same genetic variants would poten-
tially induce low-grade inflammation, and its effect would only be observed later in life, as is the case for AMD, 
a disease that is prevalent in the elderly population. In support of this hypothesis, immune genes have been 
described to have the highest rate of positive selection37. Upon examination of the amino acid conservation of the 
SNPs in the present study, in humans three complement-raising variants are the refence amino acid, compared to 
only one in primates (Supplementary Table 4).
Figure 2. Mean C3d/C3 level and frequency of genotype combinations in AMD patients and controls. 
The blue and green bars represent the percentage of individuals carrying a specific genotype combination 
within their own disease status . The green triangles and blue squares represent mean C3d/C3 values for the 
corresponding genotype combination. The only genotype combination showing a significant difference in 
complement levels between AMD patients and controls was observed for TT-GG-GA with a p-value of 3*10−4 
(after Bonferroni correction statistical significance is achieved at p < 0.007).
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A significant difference in complement levels was observed between AMD patients and controls carrying the 
TT-GG-GA genotype combination. Although the highest mean difference was observed between the groups car-
rying the TT-GA-GG combination, this difference was not significant due to the high standard error.
The four most prevalent genotype combinations are all associated with high levels of complement activation 
in AMD patients with only minor differences between the groups. The three genotype combinations that are least 
prevalent are associated with lower complement activity. If we look at the specific genotype combinations, some 
interesting observations can be made.
First of all, the TT-GG-GG genotype combination is associated with the highest complement activation levels and 
is more prevalent in AMD patients (57.3%) than in controls (43.3%). The TA-GG-GG genotype, which is only differ-
ent with respect to 1 risk allele in CFB rs4151667, is at the lower end of complement activation. The only other geno-
type combination with TA instead of TT for CFB rs4151667 is also associated with lower complement activation. This 
suggest that this SNP might be the most important of the three SNPs in the novel complotype and is the driving force 
behind the influence on complement activation. This is also evident in the results from the random forest analyses, 
where CFB rs4151667 is the strongest predictor for complement activation compared to the other individual SNPs.
Another interesting observation from Fig. 1 is the difference in complement activation between genotype 
combinations TT-GG-AA and TT-GA-GA. Both combinations include four risk alleles and two protective alleles, 
but the difference in complement activation is striking, especially in the AMD group. Perhaps the presence of two 
protective alleles in one SNP, as in the TT-GG-AA genotype combination, has a stronger influence on comple-
ment activity than the combination of two heterozygous SNPs (TT-GA-GA). Observations like ours may help to 
clarify this and warrant further research, preferentially in an even larger dataset.
One of the major strengths of this study is the use of the large EUGENDA dataset. To the best of our knowl-
edge, this is one of the largest datasets of complement activation to date. For the evaluation of mean differences in 
complement activation at a population level, as we have done in this study, a single measurement of C3 and C3d 
in each individual is sufficient. However, if complement activation would be used on an individual basis, such as 
for the selection of patients for clinical trials, multiple measurements over time would be prefered to correct for 
individual variations in complement activation.
In conclusion, the current study has demonstrated that a novel complotype composed of CFB (rs4151667) in 
combination with CFB (rs641153) and CFH(rs800292) is strongly associated with complement activation and 
AMD status. These findings are relevant in the context of future complement-lowering treatments for AMD. In 
the era of personalized medicine, we are moving towards a more individualized approach to the treatment of dis-
eases. To evaluate new treatment strategies, we need detailed information to determine how subgroups of patients 
with a higher treatment response potential should be defined. In this case, genotype-based patient stratification 
may identify those individuals that are genetically predisposed to having the highest complement levels, poten-
tially making them the best candidates for complement-inhibiting therapies in AMD.
Materials and Methods
Study population. In this study, 3042 participants from the European Genetic Database (EUGENDA, www.
eugenda.org), over the age of 50 years, were included. The study was performed in accordance with the tenets of 
the Declaration of Helsinki and the Medical Research Involving Human Subjects Act (WMO) and was approved 
by the local ethics committee of the University Hospitals in Cologne and Nijmegen. Written informed consent 
was obtained from all participants.
AMD and control status were assigned by multimodal image grading that included stereo fundus photo-
graphs, fluorescein angiograms and spectral domain optical coherence tomograms. The grading was performed 
according to the standard protocol of the Cologne Image Reading Center (CIRCL) by certified graders (TR, LE) 
as previously described38.
Age, gender and BMI were obtained by standardized interviewer-assisted questionnaires.
Complement measurements and genetic analysis. Complement component C3 and the activation 
fragment C3d were measured in serum samples as previously described9, and the C3d/C3 ratio was calculated 
as a measure of complement activation. The complement activation data were skewed and had several outliers 
at the high end of the value range. In order to reduce the risk of outlier effects distorting the data, five percent of 
the highest values from the entire dataset were excluded from our analysis. After the exclusion of the outliers, the 
remaining skeweness of the C3d/C3 data was normalized by Log10 transformation.
Genomic DNA was extracted from peripheral blood samples using standard procedures. Four SNPs, CFH 
(rs800292), CFB (rs4151667), CFB (rs641153) and C3 (rs2230199) were genotyped using the KASPar SNP 
Genotyping System by LGC Genomics.
Statistical analysis. All associations were calculated using SPSS software version 20.0 (IBM Software and 
Systems, Armonk, NY, USA). Associations with complement activation were analyzed using General Linear 
Models with C3d/C3 as the dependent variable. The models were corrected for age, gender, BMI and disease status.
The associations between AMD phenotype and the individual SNPs or the complotype were evaluated using 
logistic regression. To determine if the SNPs were independently associated with the disease, all four SNPs were 
included in the logistic regression model at once.
To avoid being relevant only to our sample set (overfitting), the most informative complotype combina-
tion was determined by calculating the variable importance in a random forest analysis using the R package 
(RandomForest version 4.6-10). In the first analysis, C3d/C3 was included as the dependent variable for the 
regression type random forest test. In the second analysis, the disease status was defined as the classifier for a 
classification type of random forest. For both analyses the number of predictors sampled for splitting at each node 
was set to two. All other options were left at default setting.
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